{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:43:30Z","timestamp":1777290210282,"version":"3.51.4"},"reference-count":275,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Postgraduate Scientific Research Innovation Project of Hunan Province","award":["No. CX20230295"],"award-info":[{"award-number":["No. CX20230295"]}]},{"name":"supported by the Fundamental Research Funds for the Central Universities of Central South University","award":["2025ZZTS0021"],"award-info":[{"award-number":["2025ZZTS0021"]}]},{"DOI":"10.13039\/501100004761","name":"Natural Science Foundation of Hunan Province of China","doi-asserted-by":"crossref","award":["No. 2023JJ60435"],"award-info":[{"award-number":["No. 2023JJ60435"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82473530"],"award-info":[{"award-number":["No. 82473530"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82373488"],"award-info":[{"award-number":["No. 82373488"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of Hunan Province of China","award":["2024JJ4077"],"award-info":[{"award-number":["2024JJ4077"]}]},{"name":"Health research project of Hunan Provincial Health Commission of China","award":["No. W20243055"],"award-info":[{"award-number":["No. W20243055"]}]},{"name":"Hunan Provincial Health High-Level Talent Scientific Research Project","award":["No.R2023041"],"award-info":[{"award-number":["No.R2023041"]}]},{"name":"Hunan Provincial Natural Science Foundation Key Project","award":["2025JJ30036"],"award-info":[{"award-number":["2025JJ30036"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-026-09133-x","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T09:21:42Z","timestamp":1777281702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An Update Comprehensive Review on Epigenetic Modifications and Therapies in Autoimmune Diseases"],"prefix":"10.1007","volume":"69","author":[{"given":"Hui","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suqing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanghan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian","family":"Jian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haijing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"9894","key":"9133_CR1","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","volume":"382","author":"M Wahren-Herlenius","year":"2013","unstructured":"Wahren-Herlenius M, D\u00f6rner T (2013) Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 382(9894):819\u2013831","journal-title":"Lancet"},{"issue":"4","key":"9133_CR2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/joim.12395","volume":"278","author":"L Wang","year":"2015","unstructured":"Wang L et al (2015) Human autoimmune diseases: a comprehensive update. J Intern Med 278(4):369\u2013395","journal-title":"J Intern Med"},{"issue":"6644","key":"9133_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1126\/science.adg2992","volume":"380","author":"A Harroud","year":"2023","unstructured":"Harroud A, Hafler DA (2023) Common genetic factors among autoimmune diseases. Science 380(6644):485\u2013490","journal-title":"Science"},{"key":"9133_CR4","doi-asserted-by":"publisher","first-page":"102266","DOI":"10.1016\/j.coi.2022.102266","volume":"80","author":"FW Miller","year":"2023","unstructured":"Miller FW (2023) The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr Opin Immunol 80:102266","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"9133_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13073-014-0060-z","volume":"6","author":"JE Castillo-Fernandez","year":"2014","unstructured":"Castillo-Fernandez JE et al (2014) Epigenetics of discordant monozygotic twins: implications for disease. Genome Med 6(7):60","journal-title":"Genome Med"},{"issue":"1","key":"9133_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/ije\/dyr184","volume":"41","author":"CH Waddington","year":"2012","unstructured":"Waddington CH (2012) The epigenotype. 1942. Int J Epidemiol 41(1):10\u20133","journal-title":"Int J Epidemiol"},{"issue":"12","key":"9133_CR7","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/s41580-018-0074-2","volume":"19","author":"K Skvortsova","year":"2018","unstructured":"Skvortsova K et al (2018) Functions and mechanisms of epigenetic inheritance in animals. Nat Rev Mol Cell Biol 19(12):774\u2013790","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"9133_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.tig.2022.10.004","volume":"39","author":"I Orsolic","year":"2023","unstructured":"Orsolic I et al (2023) Genetic and epigenetic defects of the RNA modification machinery in cancer. Trends Genet 39(1):74\u201388","journal-title":"Trends Genet"},{"issue":"1","key":"9133_CR9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41392-024-02039-0","volume":"9","author":"W Dai","year":"2024","unstructured":"Dai W et al (2024) Epigenetics-targeted drugs: current paradigms and future challenges. Signal Transduct Target Ther 9(1):332","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"9133_CR10","first-page":"376","volume":"73","author":"V Davalos","year":"2023","unstructured":"Davalos V, Esteller M (2023) Cancer epigenetics in clinical practice. CA Cancer J Clin 73(4):376\u2013424","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"9133_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","volume":"150","author":"MA Dawson","year":"2012","unstructured":"Dawson MA, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150(1):12\u201327","journal-title":"Cell"},{"issue":"1","key":"9133_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00005-007-0002-1","volume":"55","author":"F Mor","year":"2007","unstructured":"Mor F (2007) Treatment of autoimmune disease: time for a paradigm shift? Arch Immunol Ther Exp (Warsz) 55(1):13\u201318","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"3","key":"9133_CR13","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s12016-017-8640-5","volume":"55","author":"J Bakshi","year":"2018","unstructured":"Bakshi J et al (2018) Unmet needs in the pathogenesis and treatment of systemic lupus erythematosus. Clin Rev Allergy Immunol 55(3):352\u2013367","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"9133_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S2213-8587(13)70045-7","volume":"1","author":"MJ Seibel","year":"2013","unstructured":"Seibel MJ et al (2013) Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol 1(1):59\u201370","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"9133_CR15","doi-asserted-by":"publisher","first-page":"103584","DOI":"10.1016\/j.autrev.2024.103584","volume":"23","author":"MG Danieli","year":"2024","unstructured":"Danieli MG et al (2024) Exposome: epigenetics and autoimmune diseases. Autoimmun Rev 23(6):103584","journal-title":"Autoimmun Rev"},{"issue":"6990","key":"9133_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature02625","volume":"429","author":"G Egger","year":"2004","unstructured":"Egger G et al (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990):457\u2013463","journal-title":"Nature"},{"issue":"1","key":"9133_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1570159X13666150211001600","volume":"14","author":"J Peedicayil","year":"2016","unstructured":"Peedicayil J (2016) Epigenetic drugs for multiple sclerosis. Curr Neuropharmacol 14(1):3\u20139","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"9133_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s12016-009-8172-8","volume":"39","author":"M Szyf","year":"2010","unstructured":"Szyf M (2010) Epigenetic therapeutics in autoimmune disease. Clin Rev Allergy Immunol 39(1):62\u201377","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"9133_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1634\/theoncologist.10-3-176","volume":"10","author":"E Kaminskas","year":"2005","unstructured":"Kaminskas E et al (2005) FDA drug approval summary: Azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 10(3):176\u2013182","journal-title":"Oncologist"},{"issue":"11","key":"9133_CR20","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1007\/s00277-014-2126-9","volume":"93","author":"L Pleyer","year":"2014","unstructured":"Pleyer L et al (2014) Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Ann Hematol 93(11):1825\u201338","journal-title":"Ann Hematol"},{"issue":"26","key":"9133_CR21","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","volume":"383","author":"AH Wei","year":"2020","unstructured":"Wei AH et al (2020) Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med 383(26):2526\u20132537","journal-title":"N Engl J Med"},{"issue":"11","key":"9133_CR22","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nrd2180","volume":"5","author":"SD Gore","year":"2006","unstructured":"Gore SD et al (2006) Decitabine Nat Rev Drug Discov 5(11):891\u2013892","journal-title":"Decitabine Nat Rev Drug Discov"},{"issue":"6","key":"9133_CR23","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1634\/theoncologist.2015-0298","volume":"21","author":"M Nieto","year":"2016","unstructured":"Nieto M et al (2016) The European Medicines Agency review of decitabine (Dacogen) for the treatment of adult patients with acute myeloid leukemia: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Oncologist 21(6):692\u2013700","journal-title":"Oncologist"},{"issue":"13","key":"9133_CR24","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s40265-020-01389-7","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S (2020) Decitabine\/Cedazuridine: first approval. Drugs 80(13):1373\u20131378","journal-title":"Drugs"},{"issue":"10","key":"9133_CR25","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"BS Mann","year":"2007","unstructured":"Mann BS et al (2007) FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10):1247\u20131252","journal-title":"Oncologist"},{"issue":"32","key":"9133_CR26","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","volume":"27","author":"RL Piekarz","year":"2009","unstructured":"Piekarz RL et al (2009) Phase II multi-institutional trial of the histone deacetylase inhibitor Romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27(32):5410\u20135417","journal-title":"J Clin Oncol"},{"issue":"13","key":"9133_CR27","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s40265-014-0275-8","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole RM (2014) Belinostat: first global approval. Drugs 74(13):1543\u20131554","journal-title":"Drugs"},{"issue":"8","key":"9133_CR28","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y et al (2015) Results from a multicenter, open-label, pivotal phase II study of Chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 26(8):1766\u20131771","journal-title":"Ann Oncol"},{"issue":"11","key":"9133_CR29","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel JF et al (2014) Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 15(11):1195\u20131206","journal-title":"Lancet Oncol"},{"issue":"15","key":"9133_CR30","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s40265-017-0813-2","volume":"77","author":"ES Kim","year":"2017","unstructured":"Kim ES (2017) Enasidenib: first global approval. Drugs 77(15):1705\u20131711","journal-title":"Drugs"},{"issue":"25","key":"9133_CR31","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD et al (2018) Durable remissions with Ivosidenib in IDH1-Mutated relapsed or refractory AML. N Engl J Med 378(25):2386\u20132398","journal-title":"N Engl J Med"},{"issue":"5","key":"9133_CR32","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","volume":"80","author":"SM Hoy","year":"2020","unstructured":"Hoy SM (2020) Tazemetostat: first approval. Drugs 80(5):513\u2013521","journal-title":"Drugs"},{"issue":"11","key":"9133_CR33","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F et al (2020) Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 21(11):1433\u20131442","journal-title":"Lancet Oncol"},{"issue":"16","key":"9133_CR34","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40265-022-01800-5","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ (2022) Valemetostat tosilate: first approval. Drugs 82(16):1621\u20131627","journal-title":"Drugs"},{"issue":"7","key":"9133_CR35","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/S2352-3026(22)00134-X","volume":"9","author":"Y Song","year":"2022","unstructured":"Song Y et al (2022) SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial. Lancet Haematol 9(7):e493\u2013e503","journal-title":"Lancet Haematol"},{"issue":"1","key":"9133_CR36","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13148-019-0776-0","volume":"11","author":"A Ganesan","year":"2019","unstructured":"Ganesan A et al (2019) The timeline of epigenetic drug discovery: from reality to Dreams. Clin Epigenetics 11(1):174","journal-title":"Clin Epigenetics"},{"key":"9133_CR37","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1098\/rstb.2017.0069","volume":"373","author":"A Ganesan","year":"2018","unstructured":"Ganesan A (2018) Epigenetic drug discovery: a success story for cofactor interference. Philos Trans R Soc Lond B Biol Sci 373:1748","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"9133_CR38","doi-asserted-by":"publisher","first-page":"108749","DOI":"10.1016\/j.pharmthera.2024.108749","volume":"265","author":"Y Cao","year":"2025","unstructured":"Cao Y et al (2025) Exploring the landscape of post-translational modification in drug discovery. Pharmacol Ther 265:108749","journal-title":"Pharmacol Ther"},{"issue":"11","key":"9133_CR39","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.tig.2019.07.007","volume":"35","author":"RJ Schmitz","year":"2019","unstructured":"Schmitz RJ et al (2019) DNA methylation: shared and divergent features across eukaryotes. Trends Genet 35(11):818\u2013827","journal-title":"Trends Genet"},{"issue":"7","key":"9133_CR40","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrg3230","volume":"13","author":"PA Jones","year":"2012","unstructured":"Jones PA (2012) Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 13(7):484\u2013492","journal-title":"Nat Rev Genet"},{"issue":"2","key":"9133_CR41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrg.2017.80","volume":"19","author":"F Lyko","year":"2018","unstructured":"Lyko F (2018) The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat Rev Genet 19(2):81\u201392","journal-title":"Nat Rev Genet"},{"issue":"3","key":"9133_CR42","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ceb.2007.04.011","volume":"19","author":"M Weber","year":"2007","unstructured":"Weber M, Schubeler D (2007) Genomic patterns of DNA methylation: targets and function of an epigenetic mark. Curr Opin Cell Biol 19(3):273\u2013280","journal-title":"Curr Opin Cell Biol"},{"issue":"1","key":"9133_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/npp.2012.112","volume":"38","author":"LD Moore","year":"2013","unstructured":"Moore LD et al (2013) DNA methylation and its basic function. Neuropsychopharmacology 38(1):23\u201338","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"9133_CR44","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrn.2017.46","volume":"18","author":"JY Hwang","year":"2017","unstructured":"Hwang JY et al (2017) The emerging field of epigenetics in neurodegeneration and neuroprotection. Nat Rev Neurosci 18(6):347\u2013361","journal-title":"Nat Rev Neurosci"},{"key":"9133_CR45","doi-asserted-by":"publisher","first-page":"115753","DOI":"10.1016\/j.biopha.2023.115753","volume":"168","author":"L Yan","year":"2023","unstructured":"Yan L et al (2023) Insights into DNMT1 and programmed cell death in diseases. Biomed Pharmacother 168:115753","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"9133_CR46","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2174\/1389557523666230825100246","volume":"24","author":"Q Feng","year":"2024","unstructured":"Feng Q et al (2024) DNA methyltransferase 3A: A significant target for the discovery of inhibitors as potent anticancer drugs. Mini Rev Med Chem 24(5):507\u2013520","journal-title":"Mini Rev Med Chem"},{"issue":"1","key":"9133_CR47","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41392-024-01918-w","volume":"9","author":"W Yao","year":"2024","unstructured":"Yao W et al (2024) Crossing epigenetic frontiers: the intersection of novel histone modifications and diseases. Signal Transduct Target Ther 9(1):232","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"9133_CR48","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1042\/EBC20180067","volume":"63","author":"TO Tolsma","year":"2019","unstructured":"Tolsma TO, Hansen JC (2019) Post-translational modifications and chromatin dynamics. Essays Biochem 63(1):89\u201396","journal-title":"Essays Biochem"},{"issue":"4","key":"9133_CR49","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.cell.2007.05.009","volume":"129","author":"A Barski","year":"2007","unstructured":"Barski A et al (2007) High-resolution profiling of histone methylations in the human genome. Cell 129(4):823\u201337","journal-title":"Cell"},{"issue":"14","key":"9133_CR50","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.2174\/0929867328666211108105214","volume":"29","author":"S Zaib","year":"2022","unstructured":"Zaib S et al (2022) Histone modifications and their role in epigenetics of cancer. Curr Med Chem 29(14):2399\u20132411","journal-title":"Curr Med Chem"},{"key":"9133_CR51","doi-asserted-by":"publisher","first-page":"115982","DOI":"10.1016\/j.ejmech.2023.115982","volume":"264","author":"D Li","year":"2024","unstructured":"Li D et al (2024) Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: current progress and novel strategies. Eur J Med Chem 264:115982","journal-title":"Eur J Med Chem"},{"issue":"2","key":"9133_CR52","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s10555-023-10160-9","volume":"43","author":"D Tong","year":"2024","unstructured":"Tong D et al (2024) The emerging roles of histone demethylases in cancers. Cancer Metastasis Rev 43(2):795\u2013821","journal-title":"Cancer Metastasis Rev"},{"key":"9133_CR53","doi-asserted-by":"crossref","unstructured":"Zhang X et al (2021) Therapeutic potential of targeting LSD1\/ KDM1A in cancers. Pharmacol Res, 105958","DOI":"10.1016\/j.phrs.2021.105958"},{"issue":"2","key":"9133_CR54","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrm.2016.140","volume":"18","author":"BR Sabari","year":"2017","unstructured":"Sabari BR et al (2017) Metabolic regulation of gene expression through histone acylations. Nat Rev Mol Cell Biol 18(2):90\u2013101","journal-title":"Nat Rev Mol Cell Biol"},{"key":"9133_CR55","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13148-016-0225-2","volume":"8","author":"H Wapenaar","year":"2016","unstructured":"Wapenaar H, Dekker FJ (2016) Histone acetyltransferases: challenges in targeting bi-substrate enzymes. Clin Epigenetics 8:59","journal-title":"Clin Epigenetics"},{"issue":"7","key":"9133_CR56","doi-asserted-by":"publisher","first-page":"e52774","DOI":"10.15252\/embr.202152774","volume":"22","author":"S Nitsch","year":"2021","unstructured":"Nitsch S et al (2021) Histone acylations and chromatin dynamics: concepts, challenges, and links to metabolism. EMBO Rep 22(7):e52774","journal-title":"EMBO Rep"},{"issue":"19","key":"9133_CR57","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1021\/acs.accounts.1c00463","volume":"54","author":"X Li","year":"2021","unstructured":"Li X, Li XD (2021) Integrative chemical biology approaches to deciphering the histone code: a problem-driven journey. Acc Chem Res 54(19):3734\u20133747","journal-title":"Acc Chem Res"},{"key":"9133_CR58","unstructured":"Neganova ME et al (2020) Histone modifications in epigenetic regulation of cancer: perspectives and achieved progress. Semin Cancer Biol"},{"issue":"7385","key":"9133_CR59","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nature10888","volume":"482","author":"A Lujambio","year":"2012","unstructured":"Lujambio A, Lowe SW (2012) The microcosmos of cancer. Nature 482(7385):347\u2013355","journal-title":"Nature"},{"issue":"2","key":"9133_CR60","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP (2004) Micrornas: genomics, biogenesis, mechanism, and function. Cell 116(2):281\u2013297","journal-title":"Cell"},{"issue":"5","key":"9133_CR61","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nrm2885","volume":"11","author":"F Tritschler","year":"2010","unstructured":"Tritschler F et al (2010) Role of GW182 proteins and PABPC1 in the MiRNA pathway: a sense of Deja Vu. Nat Rev Mol Cell Biol 11(5):379\u2013384","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"9133_CR62","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/0008-5472.CAN-12-3731","volume":"73","author":"C Baer","year":"2013","unstructured":"Baer C et al (2013) Genome-wide epigenetic regulation of MiRNAs in cancer. Cancer Res 73(2):473\u2013477","journal-title":"Cancer Res"},{"issue":"4","key":"9133_CR63","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1111\/brv.12428","volume":"93","author":"SP Kabekkodu","year":"2018","unstructured":"Kabekkodu SP et al (2018) Clustered MiRNAs and their role in biological functions and diseases. Biol Rev Camb Philos Soc 93(4):1955\u20131986","journal-title":"Biol Rev Camb Philos Soc"},{"issue":"2","key":"9133_CR64","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/nrrheum.2013.211","volume":"10","author":"BC Richardson","year":"2014","unstructured":"Richardson BC, Patel DR (2014) Epigenetics in 2013. DNA methylation and mirna: key roles in systemic autoimmunity. Nat Rev Rheumatol 10(2):72\u201374","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"9133_CR65","doi-asserted-by":"publisher","first-page":"101741","DOI":"10.1016\/j.beem.2023.101741","volume":"37","author":"R Mart\u00ednez-Hern\u00e1ndez","year":"2023","unstructured":"Mart\u00ednez-Hern\u00e1ndez R, Marazuela M (2023) Micrornas in autoimmune thyroid diseases and their role as biomarkers. Best Pract Res Clin Endocrinol Metab 37(2):101741","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"9133_CR66","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40291-023-00646-1","volume":"27","author":"HY Abdallah","year":"2023","unstructured":"Abdallah HY et al (2023) Expression signature of immune-related MicroRNAs in autoimmune skin disease: psoriasis and vitiligo insights. Mol Diagn Ther 27(3):405\u2013423","journal-title":"Mol Diagn Ther"},{"issue":"12","key":"9133_CR67","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nrg3074","volume":"12","author":"M Esteller","year":"2011","unstructured":"Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12(12):861\u2013874","journal-title":"Nat Rev Genet"},{"issue":"3","key":"9133_CR68","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/nsmb.2480","volume":"20","author":"TR Mercer","year":"2013","unstructured":"Mercer TR, Mattick JS (2013) Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol 20(3):300\u2013307","journal-title":"Nat Struct Mol Biol"},{"issue":"5992","key":"9133_CR69","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1126\/science.1192002","volume":"329","author":"MC Tsai","year":"2010","unstructured":"Tsai MC et al (2010) Long noncoding RNA as modular scaffold of histone modification complexes. Science 329(5992):689\u2013693","journal-title":"Science"},{"issue":"28","key":"9133_CR70","doi-asserted-by":"publisher","first-page":"11667","DOI":"10.1073\/pnas.0904715106","volume":"106","author":"AM Khalil","year":"2009","unstructured":"Khalil AM et al (2009) Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A 106(28):11667\u201311672","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9133_CR71","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/ijms20225573","volume":"20","author":"X Zhang","year":"2019","unstructured":"Zhang X et al (2019) Mechanisms and functions of long Non-Coding RNAs at multiple regulatory levels. Int J Mol Sci 20:22","journal-title":"Int J Mol Sci"},{"issue":"1","key":"9133_CR72","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12943-024-02041-8","volume":"23","author":"Y Li","year":"2024","unstructured":"Li Y et al (2024) The role of RNA methylation in tumor immunity and its potential in immunotherapy. Mol Cancer 23(1):130","journal-title":"Mol Cancer"},{"key":"9133_CR73","doi-asserted-by":"publisher","first-page":"105937","DOI":"10.1016\/j.phrs.2021.105937","volume":"174","author":"B Yang","year":"2021","unstructured":"Yang B et al (2021) RNA methylation and cancer treatment. Pharmacol Res 174:105937","journal-title":"Pharmacol Res"},{"issue":"10","key":"9133_CR74","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1073\/pnas.71.10.3971","volume":"71","author":"R Desrosiers","year":"1974","unstructured":"Desrosiers R et al (1974) Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci U S A 71(10):3971\u20133975","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"9133_CR75","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.cell.2012.05.003","volume":"149","author":"KD Meyer","year":"2012","unstructured":"Meyer KD et al (2012) Comprehensive analysis of mRNA methylation reveals enrichment in 3\u2019 UTRs and near stop codons. Cell 149(7):1635\u20131646","journal-title":"Cell"},{"issue":"7397","key":"9133_CR76","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nature11112","volume":"485","author":"D Dominissini","year":"2012","unstructured":"Dominissini D et al (2012) Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature 485(7397):201\u2013206","journal-title":"Nature"},{"issue":"1","key":"9133_CR77","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12943-023-01841-8","volume":"22","author":"SW Yue","year":"2023","unstructured":"Yue SW et al (2023) m6A-regulated tumor glycolysis: new advances in epigenetics and metabolism. Mol Cancer 22(1):137","journal-title":"Mol Cancer"},{"issue":"13","key":"9133_CR78","doi-asserted-by":"publisher","first-page":"7239","DOI":"10.1093\/nar\/gkab378","volume":"49","author":"S Oerum","year":"2021","unstructured":"Oerum S et al (2021) A comprehensive review of m6A\/m6Am RNA methyltransferase structures. Nucleic Acids Res 49(13):7239\u20137255","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"9133_CR79","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/17460441.2017.1295954","volume":"12","author":"V Prachayasittikul","year":"2017","unstructured":"Prachayasittikul V et al (2017) Exploring the epigenetic drug discovery landscape. Expert Opin Drug Discov 12(4):345\u2013362","journal-title":"Expert Opin Drug Discov"},{"key":"9133_CR80","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3389\/fimmu.2018.00497","volume":"9","author":"Z Zhang","year":"2018","unstructured":"Zhang Z et al (2018) Overall downregulation of mRNAs and enrichment of H3K4me3 change near Genome-Wide association study signals in systemic lupus erythematosus: Cell-Specific effects. Front Immunol 9:497","journal-title":"Front Immunol"},{"issue":"6","key":"9133_CR81","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B et al (2012) Results from a pivotal, open-label, phase II study of Romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30(6):631\u2013636","journal-title":"J Clin Oncol"},{"key":"9133_CR82","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1756-8722-7-11","volume":"7","author":"B Coiffier","year":"2014","unstructured":"Coiffier B et al (2014) Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol 7:11","journal-title":"J Hematol Oncol"},{"key":"9133_CR83","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.3389\/fimmu.2019.02512","volume":"10","author":"J Ren","year":"2019","unstructured":"Ren J et al (2019) Selective histone deacetylase 6 Inhibition normalizes B cell activation and germinal center formation in a model of systemic lupus erythematosus. Front Immunol 10:2512","journal-title":"Front Immunol"},{"key":"9133_CR84","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.clim.2015.11.007","volume":"162","author":"NL Regna","year":"2016","unstructured":"Regna NL et al (2016) Specific HDAC6 Inhibition by ACY-738 reduces SLE pathogenesis in NZB\/W mice. Clin Immunol 162:58\u201373","journal-title":"Clin Immunol"},{"issue":"5","key":"9133_CR85","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1128\/MCB.01154-06","volume":"28","author":"Y Zhang","year":"2008","unstructured":"Zhang Y et al (2008) Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 28(5):1688\u20131701","journal-title":"Mol Cell Biol"},{"issue":"3","key":"9133_CR86","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/15592294.2015.1009764","volume":"10","author":"YT Leung","year":"2015","unstructured":"Leung YT et al (2015) Interferon regulatory factor 1 and histone H4 acetylation in systemic lupus erythematosus. Epigenetics 10(3):191\u2013199","journal-title":"Epigenetics"},{"issue":"3","key":"9133_CR87","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ (2017) Microrna therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 16(3):203\u2013222","journal-title":"Nat Rev Drug Discov"},{"key":"9133_CR88","doi-asserted-by":"publisher","first-page":"102438","DOI":"10.1016\/j.jaut.2020.102438","volume":"109","author":"L Zhang","year":"2020","unstructured":"Zhang L et al (2020) Clinical significance of MiRNAs in autoimmunity. J Autoimmun 109:102438","journal-title":"J Autoimmun"},{"issue":"1","key":"9133_CR89","doi-asserted-by":"publisher","first-page":"e86787","DOI":"10.1371\/journal.pone.0086787","volume":"9","author":"CP Wong","year":"2014","unstructured":"Wong CP et al (2014) Effects of sulforaphane and 3,3\u2019-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells. PLoS One 9(1):e86787","journal-title":"PLoS One"},{"issue":"5","key":"9133_CR90","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/art.39031","volume":"67","author":"AP Cribbs","year":"2015","unstructured":"Cribbs AP et al (2015) Methotrexate restores regulatory T cell function through demethylation of the FoxP3 upstream enhancer in patients with rheumatoid arthritis. Arthritis Rheumatol 67(5):1182\u201392","journal-title":"Arthritis Rheumatol"},{"key":"9133_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212170","author":"M Payet","year":"2021","unstructured":"Payet M et al (2021) Epigenetic regulation (including micro-RNAs, DNA methylation and histone modifications) of rheumatoid arthritis: a systematic review. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms222212170","journal-title":"Int J Mol Sci"},{"key":"9133_CR92","doi-asserted-by":"publisher","first-page":"5648987","DOI":"10.1155\/2019\/5648987","volume":"2019","author":"DS Kim","year":"2019","unstructured":"Kim DS et al (2019) Suberoylanilide hydroxamic acid attenuates autoimmune arthritis by suppressing Th17 cells through NR1D1 Inhibition. Mediators Inflamm 2019:5648987","journal-title":"Mediators Inflamm"},{"issue":"5","key":"9133_CR93","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/1756-185X.12501","volume":"18","author":"J Lee","year":"2015","unstructured":"Lee J et al (2015) A novel histone deacetylase 6-selective inhibitor suppresses synovial inflammation and joint destruction in a collagen antibody-induced arthritis mouse model. Int J Rheum Dis 18(5):514\u2013523","journal-title":"Int J Rheum Dis"},{"key":"9133_CR94","doi-asserted-by":"crossref","unstructured":"Park JK et al (2021) Inhibition of histone deacetylase 6 suppresses inflammatory responses and invasiveness of fibroblast-like-synoviocytes in inflammatory arthritis. Arthritis Res Ther 23(1)","DOI":"10.1186\/s13075-021-02561-4"},{"issue":"8","key":"9133_CR95","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1021\/acs.jmedchem.7b01593","volume":"61","author":"A Sellmer","year":"2018","unstructured":"Sellmer A et al (2018) Marbostat-100 defines a new class of potent and selective antiinflammatory and antirheumatic histone deacetylase 6 inhibitors. J Med Chem 61(8):3454\u20133477","journal-title":"J Med Chem"},{"issue":"4","key":"9133_CR96","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.bbrc.2014.01.195","volume":"444","author":"TT Wada","year":"2014","unstructured":"Wada TT et al (2014) Aberrant histone acetylation contributes to elevated interleukin-6 production in rheumatoid arthritis synovial fibroblasts. Biochem Biophys Res Commun 444(4):682\u2013686","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"9133_CR97","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/jcb.26205","volume":"119","author":"F Tavasolian","year":"2018","unstructured":"Tavasolian F et al (2018) Altered expression of MicroRNAs in rheumatoid arthritis. J Cell Biochem 119(1):478\u2013487","journal-title":"J Cell Biochem"},{"issue":"13","key":"9133_CR98","doi-asserted-by":"publisher","first-page":"17227","DOI":"10.18632\/aging.203201","volume":"13","author":"YY Law","year":"2021","unstructured":"Law YY et al (2021) MiR-let-7c-5p and miR-149-5p inhibit proinflammatory cytokine production in osteoarthritis and rheumatoid arthritis synovial fibroblasts. Aging Albany NY 13(13):17227\u201317236","journal-title":"Aging Albany NY"},{"key":"9133_CR99","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/biom10071044","volume":"10","author":"V Lodde","year":"2020","unstructured":"Lodde V et al (2020) Long noncoding RNAs and circular RNAs in autoimmune diseases. Biomolecules 10:7","journal-title":"Biomolecules"},{"key":"9133_CR100","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.expneurol.2012.12.006","volume":"241","author":"Z Ge","year":"2013","unstructured":"Ge Z et al (2013) Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis. Exp Neurol 241:56\u201366","journal-title":"Exp Neurol"},{"key":"9133_CR101","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.neuroscience.2012.07.013","volume":"221","author":"Z Zhang","year":"2012","unstructured":"Zhang Z et al (2012) Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats. Neuroscience 221:140\u201350","journal-title":"Neuroscience"},{"issue":"1","key":"9133_CR102","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40246-018-0163-5","volume":"12","author":"H He","year":"2018","unstructured":"He H et al (2018) The Tale of histone modifications and its role in multiple sclerosis. Hum Genomics 12(1):31","journal-title":"Hum Genomics"},{"issue":"10","key":"9133_CR103","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41584-021-00683-2","volume":"17","author":"PS Tsou","year":"2021","unstructured":"Tsou PS et al (2021) Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential. Nat Rev Rheumatol 17(10):596\u2013607","journal-title":"Nat Rev Rheumatol"},{"issue":"10103","key":"9133_CR104","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390(10103):1685\u20131699","journal-title":"Lancet"},{"issue":"1","key":"9133_CR105","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/annrheumdis-2014-205740","volume":"75","author":"P Zerr","year":"2016","unstructured":"Zerr P et al (2016) Sirt1 regulates canonical TGF-beta signalling to control fibroblast activation and tissue fibrosis. Ann Rheum Dis 75(1):226\u2013233","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"9133_CR106","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1002\/art.22759","volume":"56","author":"LC Huber","year":"2007","unstructured":"Huber LC et al (2007) Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum 56(8):2755\u20132764","journal-title":"Arthritis Rheum"},{"issue":"5","key":"9133_CR107","first-page":"595","volume":"72","author":"ML Sosulski","year":"2017","unstructured":"Sosulski ML et al (2017) Sirtuin 3 deregulation promotes pulmonary fibrosis. J Gerontol Biol Sci Med Sci 72(5):595\u2013602","journal-title":"J Gerontol Biol Sci Med Sci"},{"issue":"2","key":"9133_CR108","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s43587-021-00027-5","volume":"1","author":"M Rehan","year":"2021","unstructured":"Rehan M et al (2021) Restoration of SIRT3 gene expression by airway delivery resolves age-associated persistent lung fibrosis in mice. Nat Aging 1(2):205\u2013217","journal-title":"Nat Aging"},{"issue":"5","key":"9133_CR109","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jid.2018.11.007","volume":"139","author":"CL Gallant-Behm","year":"2019","unstructured":"Gallant-Behm CL et al (2019) A MicroRNA-29 mimic (Remlarsen) represses extracellular matrix expression and fibroplasia in the skin. J Invest Dermatol 139(5):1073\u20131081","journal-title":"J Invest Dermatol"},{"issue":"9","key":"9133_CR110","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/jbt.21807","volume":"30","author":"S Khan","year":"2016","unstructured":"Khan S, Jena G (2016) Valproic acid improves glucose homeostasis by increasing Beta-cell proliferation, function, and reducing its apoptosis through HDAC inhibition in juvenile diabetic rat. J Biochem Mol Toxicol 30(9):438\u2013446","journal-title":"J Biochem Mol Toxicol"},{"issue":"3","key":"9133_CR111","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/ejh.14134","volume":"112","author":"X Zhang","year":"2024","unstructured":"Zhang X et al (2024) DNMTs-mediated SOCS3 methylation promotes the occurrence and development of AML. Eur J Haematol 112(3):439\u2013449","journal-title":"Eur J Haematol"},{"issue":"1","key":"9133_CR112","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12575-025-00296-z","volume":"27","author":"Y Zhang","year":"2025","unstructured":"Zhang Y et al (2025) SOCS3: an immunological biomarker offering potential therapeutic targets for malignant tumors. Biol Proced Online 27(1):36","journal-title":"Biol Proced Online"},{"issue":"1","key":"9133_CR113","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.clim.2009.06.010","volume":"133","author":"A Sharabi","year":"2009","unstructured":"Sharabi A et al (2009) A tolerogenic peptide that induces suppressor of cytokine signaling (SOCS)-1 restores the aberrant control of IFN-gamma signaling in lupus-affected (NZB x NZW)F1 mice. Clin Immunol 133(1):61\u201368","journal-title":"Clin Immunol"},{"issue":"1","key":"9133_CR114","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41392-025-02168-0","volume":"10","author":"X Dai","year":"2025","unstructured":"Dai X et al (2025) Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics. Signal Transduct Target Ther 10(1):102","journal-title":"Signal Transduct Target Ther"},{"key":"9133_CR115","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jaut.2017.04.003","volume":"83","author":"Z Xiang","year":"2017","unstructured":"Xiang Z et al (2017) The epigenetic mechanism for discordance of autoimmunity in monozygotic twins. J Autoimmun 83:43\u201350","journal-title":"J Autoimmun"},{"key":"9133_CR116","doi-asserted-by":"publisher","first-page":"102359","DOI":"10.1016\/j.jaut.2019.102359","volume":"110","author":"MD Catalina","year":"2020","unstructured":"Catalina MD et al (2020) The pathogenesis of systemic lupus erythematosus: Harnessing big data to understand the molecular basis of lupus. J Autoimmun 110:102359","journal-title":"J Autoimmun"},{"issue":"4","key":"9133_CR117","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1517\/14728222.2014.888415","volume":"18","author":"W Stohl","year":"2014","unstructured":"Stohl W (2014) Therapeutic targeting of the BAFF\/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets 18(4):473\u2013489","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"9133_CR118","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/art.27363","volume":"62","author":"Y Li","year":"2010","unstructured":"Li Y et al (2010) Overexpression of the growth arrest and DNA damage-induced 45\u03b1 gene contributes to autoimmunity by promoting DNA demethylation in lupus T cells. Arthr Rhuem 62(5):1438\u20131447","journal-title":"Arthr Rhuem"},{"key":"9133_CR119","first-page":"1","volume":"2013","author":"Y Li","year":"2013","unstructured":"Li Y et al (2013) A possible role of HMGB1 in DNA demethylation in CD4\u2009+\u2009T cells from patients with systemic lupus erythematosus. Clin Dev Immunol 2013:1\u20135","journal-title":"Clin Dev Immunol"},{"issue":"12","key":"9133_CR120","doi-asserted-by":"publisher","first-page":"6773","DOI":"10.4049\/jimmunol.0904060","volume":"184","author":"W Pan","year":"2010","unstructured":"Pan W et al (2010) MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4\u2009+\u2009T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol 184(12):6773\u20136781","journal-title":"J Immunol"},{"issue":"1","key":"9133_CR121","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jaut.2010.02.002","volume":"35","author":"M Zhao","year":"2010","unstructured":"Zhao M et al (2010) Epigenetics and SLE: RFX1 downregulation causes CD11a and CD70 overexpression by altering epigenetic modifications in lupus CD4\u2009+\u2009T cells. J Autoimmun 35(1):58\u201369","journal-title":"J Autoimmun"},{"issue":"7","key":"9133_CR122","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.it.2018.04.006","volume":"39","author":"N Huang","year":"2018","unstructured":"Huang N, Perl A (2018) Metabolism as a target for modulation in autoimmune diseases. Trends Immunol 39(7):562\u2013576","journal-title":"Trends Immunol"},{"issue":"12","key":"9133_CR123","doi-asserted-by":"publisher","first-page":"102984","DOI":"10.1016\/j.autrev.2021.102984","volume":"20","author":"C Geier","year":"2021","unstructured":"Geier C, Perl A (2021) Therapeutic mTOR blockade in systemic autoimmunity: implications for antiviral immunity and extension of lifespan. Autoimmun Rev 20(12):102984","journal-title":"Autoimmun Rev"},{"issue":"4","key":"9133_CR124","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2217\/epi-2016-0096","volume":"9","author":"CM Hedrich","year":"2017","unstructured":"Hedrich CM et al (2017) DNA methylation in systemic lupus erythematosus. Epigenomics 9(4):505\u2013525","journal-title":"Epigenomics"},{"issue":"3","key":"9133_CR125","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/art.40380","volume":"70","author":"H Kato","year":"2018","unstructured":"Kato H, Perl A (2018) Blockade of Treg cell differentiation and function by the interleukin-21-mechanistic target of rapamycin axis via suppression of autophagy in patients with systemic lupus erythematosus. Arthritis Rheumatol 70(3):427\u2013438","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"9133_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbadis.2018.10.007","volume":"1865","author":"G Shi","year":"2019","unstructured":"Shi G et al (2019) mTOR inhibitor INK128 attenuates systemic lupus erythematosus by regulating inflammation-induced CD11b(+)Gr1(+) cells. Biochim Biophys Acta Mol Basis Dis 1865(1):1\u201313","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"9133_CR127","doi-asserted-by":"crossref","unstructured":"Zhang Q et al (2016) Increased Set1 binding at the promoter induces aberrant epigenetic alterations and up-regulates cyclic adenosine 5\u2019-monophosphate response element modulator alpha in systemic lupus erythematosus. Clin Epigenetics 8 (1)","DOI":"10.1186\/s13148-016-0294-2"},{"issue":"50","key":"9133_CR128","doi-asserted-by":"publisher","first-page":"43437","DOI":"10.1074\/jbc.M111.299313","volume":"286","author":"T Rauen","year":"2011","unstructured":"Rauen T et al (2011) cAMP-responsive element modulator (CREM)alpha protein induces Interleukin 17A expression and mediates epigenetic alterations at the Interleukin-17A gene locus in patients with systemic lupus erythematosus. J Biol Chem 286(50):43437\u201343446","journal-title":"J Biol Chem"},{"issue":"41","key":"9133_CR129","doi-asserted-by":"publisher","first-page":"16606","DOI":"10.1073\/pnas.1210129109","volume":"109","author":"CM Hedrich","year":"2012","unstructured":"Hedrich CM et al (2012) cAMP response element modulator alpha controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus. Proc Natl Acad Sci U S A 109(41):16606\u201316611","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"9133_CR130","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1074\/jbc.M113.523605","volume":"289","author":"CM Hedrich","year":"2014","unstructured":"Hedrich CM et al (2014) cAMP responsive element modulator (CREM) alpha mediates chromatin remodeling of CD8 during the generation of CD3\u2009+\u2009CD4- CD8- T cells. J Biol Chem 289(4):2361\u20132370","journal-title":"J Biol Chem"},{"issue":"3","key":"9133_CR131","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s12016-015-8497-4","volume":"50","author":"PL Meroni","year":"2016","unstructured":"Meroni PL, Penatti AE (2016) Epigenetics and systemic lupus erythematosus: unmet needs. Clin Rev Allergy Immunol 50(3):367\u2013376","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"9133_CR132","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.clim.2014.09.002","volume":"155","author":"Y Guo","year":"2014","unstructured":"Guo Y et al (2014) Epigenetics in the treatment of systemic lupus erythematosus: potential clinical application. Clin Immunol 155(1):79\u201390","journal-title":"Clin Immunol"},{"issue":"5","key":"9133_CR133","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nrrheum.2011.16","volume":"7","author":"E Ballestar","year":"2011","unstructured":"Ballestar E (2011) Epigenetic alterations in autoimmune rheumatic diseases. Nat Rev Rheumatol 7(5):263\u2013271","journal-title":"Nat Rev Rheumatol"},{"key":"9133_CR134","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.abb.2014.04.019","volume":"563","author":"M Nihal","year":"2014","unstructured":"Nihal M et al (2014) Methotrexate inhibits the viability of human melanoma cell lines and enhances Fas\/Fas-ligand expression, apoptosis and response to interferon-alpha: rationale for its use in combination therapy. Arch Biochem Biophys 563:101\u2013107","journal-title":"Arch Biochem Biophys"},{"issue":"11","key":"9133_CR135","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1021\/tx2003849","volume":"24","author":"J Zhang","year":"2011","unstructured":"Zhang J et al (2011) Cyclophosphamide perturbs cytosine methylation in Jurkat-T cells through LSD1-mediated stabilization of DNMT1 protein. Chem Res Toxicol 24(11):2040\u20132043","journal-title":"Chem Res Toxicol"},{"issue":"10","key":"9133_CR136","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1158\/1078-0432.CCR-04-2135","volume":"11","author":"E Kaminskas","year":"2005","unstructured":"Kaminskas E et al (2005) Approval summary: Azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11(10):3604\u20133608","journal-title":"Clin Cancer Res"},{"key":"9133_CR137","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.semcancer.2020.05.010","volume":"72","author":"KK Wong","year":"2021","unstructured":"Wong KK (2021) DNMT1: a key drug target in triple-negative breast cancer. Semin Cancer Biol 72:198\u2013213","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"9133_CR138","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois D et al (2015) DNA-Demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162(5):961\u2013973","journal-title":"Cell"},{"issue":"5","key":"9133_CR139","first-page":"974","volume":"162","author":"KB Chiappinelli","year":"2015","unstructured":"Chiappinelli KB et al (2015) Inhibiting DNA methylation causes an interferon response in cancer via DsRNA. Including Endogenous Retroviruses Cell 162(5):974\u2013986","journal-title":"Including Endogenous Retroviruses Cell"},{"issue":"6","key":"9133_CR140","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1182\/blood.2019004143","volume":"136","author":"G Garcia-Manero","year":"2020","unstructured":"Garcia-Manero G et al (2020) Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study. Blood 136(6):674\u2013683","journal-title":"Blood"},{"issue":"4","key":"9133_CR141","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2174\/15680096113139990077","volume":"13","author":"V Singh","year":"2013","unstructured":"Singh V et al (2013) DNA methyltransferase-1 inhibitors as epigenetic therapy for cancer. Curr Cancer Drug Targets 13(4):379\u2013399","journal-title":"Curr Cancer Drug Targets"},{"issue":"15","key":"9133_CR142","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1073\/pnas.0610434104","volume":"104","author":"L Mazari","year":"2007","unstructured":"Mazari L et al (2007) Subversion of B lymphocyte tolerance by hydralazine, a potential mechanism for drug-induced lupus. Proc Natl Acad Sci U S A 104(15):6317\u20136322","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"49","key":"9133_CR143","doi-asserted-by":"publisher","first-page":"40749","DOI":"10.1074\/jbc.M505593200","volume":"280","author":"BH Lee","year":"2005","unstructured":"Lee BH et al (2005) Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem 280(49):40749\u201340756","journal-title":"J Biol Chem"},{"key":"9133_CR144","doi-asserted-by":"crossref","unstructured":"Marion MC et al (2021) Nucleic acid-sensing and interferon-inducible pathways show differential methylation in MZ twins discordant for lupus and overexpression in independent lupus samples: implications for pathogenic mechanism and drug targeting. Genes (Basel) 12(12)","DOI":"10.3390\/genes12121898"},{"issue":"6","key":"9133_CR145","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1021\/pr050188r","volume":"4","author":"BA Garcia","year":"2005","unstructured":"Garcia BA et al (2005) Resetting the epigenetic histone code in the MRL-lpr\/lpr mouse model of lupus by histone deacetylase Inhibition. J Proteome Res 4(6):2032\u20132042","journal-title":"J Proteome Res"},{"key":"9133_CR146","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.imlet.2021.09.007","volume":"240","author":"P Gautam","year":"2021","unstructured":"Gautam P et al (2021) Global histone modification analysis reveals hypoacetylated H3 and H4 histones in B cells from systemic lupus erythematosus patients. Immunol Lett 240:41\u201345","journal-title":"Immunol Lett"},{"issue":"2","key":"9133_CR147","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12011-017-1206-9","volume":"184","author":"H Hu","year":"2018","unstructured":"Hu H et al (2018) Effects of arsenic trioxide on INF-gamma gene expression in MRL\/lpr mice and human lupus. Biol Trace Elem Res 184(2):391\u2013397","journal-title":"Biol Trace Elem Res"},{"issue":"11","key":"9133_CR148","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41419-021-04323-1","volume":"12","author":"Y Tang","year":"2021","unstructured":"Tang Y et al (2021) A preliminary study of KAT2A on cGAS-related immunity in inflammation amplification of systemic lupus erythematosus. Cell Death Dis 12(11):1036","journal-title":"Cell Death Dis"},{"issue":"6","key":"9133_CR149","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2217\/epi.15.47","volume":"7","author":"L Shi","year":"2015","unstructured":"Shi L et al (2015) Monocyte enhancers are highly altered in systemic lupus erythematosus. Epigenomics 7(6):921\u2013935","journal-title":"Epigenomics"},{"issue":"5","key":"9133_CR150","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/rheumatology\/kew508","volume":"56","author":"H Zhao","year":"2017","unstructured":"Zhao H et al (2017) TNFAIP3 downregulation mediated by histone modification contributes to T-cell dysfunction in systemic lupus erythematosus. Rheumatology (Oxford) 56(5):835\u2013843","journal-title":"Rheumatology (Oxford)"},{"key":"9133_CR151","doi-asserted-by":"crossref","unstructured":"Fan J et al (2021) Kdm5a promotes B cell activation in systemic lupus erythematosus via downregulation of A20 by histone modification. Pathol Res Pract, 153653","DOI":"10.1016\/j.prp.2021.153653"},{"key":"9133_CR152","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/978-981-15-3449-2_7","volume":"1253","author":"H Wu","year":"2020","unstructured":"Wu H et al (2020) The epigenetics of lupus erythematosus. Adv Exp Med Biol 1253:185\u2013207","journal-title":"Adv Exp Med Biol"},{"key":"9133_CR153","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072356","author":"A von Knethen","year":"2020","unstructured":"von Knethen A et al (2020) Histone deacetylation inhibitors as modulators of regulatory T cells. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21072356","journal-title":"Int J Mol Sci"},{"issue":"1","key":"9133_CR154","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.clim.2014.01.002","volume":"151","author":"NL Regna","year":"2014","unstructured":"Regna NL et al (2014) Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo. Clin Immunol 151(1):29\u201342","journal-title":"Clin Immunol"},{"issue":"14","key":"9133_CR155","doi-asserted-by":"publisher","first-page":"eaay2793","DOI":"10.1126\/sciadv.aay2793","volume":"6","author":"H Gan","year":"2020","unstructured":"Gan H et al (2020) B cell Sirt1 deacetylates histone and non-histone proteins for epigenetic modulation of AID expression and the antibody response. Sci Adv 6(14):eaay2793","journal-title":"Sci Adv"},{"key":"9133_CR156","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19124007","author":"J Ren","year":"2018","unstructured":"Ren J et al (2018) The impact of protein acetylation\/deacetylation on systemic lupus erythematosus. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19124007","journal-title":"Int J Mol Sci"},{"issue":"12","key":"9133_CR157","first-page":"1317","volume":"32","author":"MD Vieson","year":"2017","unstructured":"Vieson MD et al (2017) Treatment with a selective histone deacetylase 6 inhibitor decreases lupus nephritis in NZB\/W mice. Histol Histopathol 32(12):1317\u20131332","journal-title":"Histol Histopathol"},{"issue":"1","key":"9133_CR158","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cei.13046","volume":"191","author":"J Ren","year":"2018","unstructured":"Ren J et al (2018) Selective HDAC6 Inhibition decreases early stage of lupus nephritis by down-regulating both innate and adaptive immune responses. Clin Exp Immunol 191(1):19\u201331","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"9133_CR159","doi-asserted-by":"publisher","first-page":"17297","DOI":"10.1038\/s41598-018-35602-1","volume":"8","author":"EW Choi","year":"2018","unstructured":"Choi EW et al (2018) CKD-506, a novel HDAC6-selective inhibitor, improves renal outcomes and survival in a mouse model of systemic lupus erythematosus. Sci Rep 8(1):17297","journal-title":"Sci Rep"},{"issue":"12","key":"9133_CR160","doi-asserted-by":"publisher","first-page":"8486","DOI":"10.1021\/acs.jmedchem.1c00420","volume":"64","author":"K Toutah","year":"2021","unstructured":"Toutah K et al (2021) Development of HDAC inhibitors exhibiting therapeutic potential in T-Cell prolymphocytic leukemia. J Med Chem 64(12):8486\u20138509","journal-title":"J Med Chem"},{"key":"9133_CR161","doi-asserted-by":"publisher","first-page":"110607","DOI":"10.1016\/j.biopha.2020.110607","volume":"131","author":"SS Liu","year":"2020","unstructured":"Liu SS et al (2020) HDAC11: a rising star in epigenetics. Biomed Pharmacother 131:110607","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"9133_CR162","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrd2227","volume":"6","author":"S Grant","year":"2007","unstructured":"Grant S et al (2007) Vorinostat. Nat Rev Drug Discov 6(1):21\u201322","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"9133_CR163","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1172\/JCI16153","volume":"111","author":"N Mishra","year":"2003","unstructured":"Mishra N et al (2003) Histone deacetylase inhibitors modulate renal disease in the MRL-lpr\/lpr mouse. J Clin Invest 111(4):539\u2013552","journal-title":"J Clin Invest"},{"issue":"6","key":"9133_CR164","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.4049\/jimmunol.173.6.4171","volume":"173","author":"CM Reilly","year":"2004","unstructured":"Reilly CM et al (2004) Modulation of renal disease in MRL\/lpr mice by suberoylanilide hydroxamic acid. J Immunol 173(6):4171\u20134178","journal-title":"J Immunol"},{"issue":"1","key":"9133_CR165","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13075-016-1081-3","volume":"18","author":"VL Souliotis","year":"2016","unstructured":"Souliotis VL et al (2016) Defective DNA repair and chromatin organization in patients with quiescent systemic lupus erythematosus. Arthritis Res Ther 18(1):182","journal-title":"Arthritis Res Ther"},{"issue":"23","key":"9133_CR166","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor OA et al (2015) Belinostat in patients with relapsed or refractory peripheral T-Cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol 33(23):2492\u20132499","journal-title":"J Clin Oncol"},{"issue":"6","key":"9133_CR167","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40265-015-0388-8","volume":"75","author":"KP Garnock-Jones","year":"2015","unstructured":"Garnock-Jones KP (2015) Panobinostat: first global approval. Drugs 75(6):695\u2013704","journal-title":"Drugs"},{"key":"9133_CR168","doi-asserted-by":"publisher","first-page":"6838","DOI":"10.1038\/ncomms7838","volume":"6","author":"M Waibel","year":"2015","unstructured":"Waibel M et al (2015) Manipulation of B-cell responses with histone deacetylase inhibitors. Nat Commun 6:6838","journal-title":"Nat Commun"},{"issue":"7","key":"9133_CR169","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/art.41208","volume":"72","author":"M Zhang","year":"2020","unstructured":"Zhang M et al (2020) Methionine commits cells to differentiate into plasmablasts through epigenetic regulation of BTB and CNC homolog 2 by the methyltransferase EZH2. Arthritis Rheumatol 72(7):1143\u20131153","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"9133_CR170","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.4049\/jimmunol.1701470","volume":"200","author":"M Guo","year":"2018","unstructured":"Guo M et al (2018) EZH2 represses the B cell transcriptional program and regulates antibody-Secreting cell metabolism and antibody production. J Immunol 200(3):1039\u20131052","journal-title":"J Immunol"},{"key":"9133_CR171","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3389\/fimmu.2018.00875","volume":"9","author":"E Weeding","year":"2018","unstructured":"Weeding E, Sawalha AH (2018) Deoxyribonucleic acid methylation in systemic lupus erythematosus: implications for future clinical practice. Front Immunol 9:875","journal-title":"Front Immunol"},{"issue":"10","key":"9133_CR172","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/art.40931","volume":"71","author":"DM Rohraff","year":"2019","unstructured":"Rohraff DM et al (2019) Inhibition of EZH2 ameliorates lupus-like disease in MRL\/lpr mice. Arthritis Rheumatol 71(10):1681\u20131690","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"9133_CR173","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13075-020-02225-9","volume":"22","author":"Y Zhen","year":"2020","unstructured":"Zhen Y et al (2020) Ezh2-mediated epigenetic modification is required for allogeneic T cell-induced lupus disease. Arthritis Res Ther 22(1):133","journal-title":"Arthritis Res Ther"},{"key":"9133_CR174","doi-asserted-by":"publisher","first-page":"699684","DOI":"10.3389\/fimmu.2021.699684","volume":"12","author":"M Chi","year":"2021","unstructured":"Chi M et al (2021) Immunological involvement of MicroRNAs in the key events of systemic lupus erythematosus. Front Immunol 12:699684","journal-title":"Front Immunol"},{"key":"9133_CR175","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2147\/DDDT.S288859","volume":"15","author":"S Zhang","year":"2021","unstructured":"Zhang S et al (2021) The risks of MiRNA therapeutics: in a drug target perspective. Drug Des Devel Ther 15:721\u2013733","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"9133_CR176","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D et al (2018) Patisiran, an RNAi Therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11\u201321","journal-title":"N Engl J Med"},{"issue":"24","key":"9133_CR177","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","volume":"382","author":"M Balwani","year":"2020","unstructured":"Balwani M et al (2020) Phase 3 trial of RNAi therapeutic Givosiran for acute intermittent porphyria. N Engl J Med 382(24):2289\u20132301","journal-title":"N Engl J Med"},{"issue":"13","key":"9133_CR178","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","volume":"384","author":"SF Garrelfs","year":"2021","unstructured":"Garrelfs SF et al (2021) Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med 384(13):1216\u20131226","journal-title":"N Engl J Med"},{"issue":"10126","key":"9133_CR179","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","volume":"391","author":"Z-W Lai","year":"2018","unstructured":"Lai Z-W et al (2018) Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial. Lancet 391(10126):1186\u20131196","journal-title":"Lancet"},{"issue":"1","key":"9133_CR180","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.clim.2015.03.005","volume":"158","author":"Y Yang","year":"2015","unstructured":"Yang Y et al (2015) The effect of mycophenolic acid on epigenetic modifications in lupus CD4\u2009+\u2009T cells. Clin Immunol 158(1):67\u201376","journal-title":"Clin Immunol"},{"issue":"9","key":"9133_CR181","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1177\/0961203315570685","volume":"24","author":"Q Tang","year":"2015","unstructured":"Tang Q et al (2015) Mycophenolic acid upregulates miR-142-3P\/5P and miR-146a in lupus CD4\u2009+\u2009T cells. Lupus 24(9):935\u2013942","journal-title":"Lupus"},{"issue":"3","key":"9133_CR182","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.taap.2012.07.007","volume":"263","author":"LM Beaver","year":"2012","unstructured":"Beaver LM et al (2012) 3,3\u2019-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells. Toxicol Appl Pharmacol 263(3):345\u2013351","journal-title":"Toxicol Appl Pharmacol"},{"key":"9133_CR183","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS et al (2018) Rheumatoid arthritis. Nat Rev Dis Primers 4:18001","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"9133_CR184","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","volume":"46","author":"GS Firestein","year":"2017","unstructured":"Firestein GS, McInnes IB (2017) Immunopathogenesis of rheumatoid arthritis. Immunity 46(2):183\u2013196","journal-title":"Immunity"},{"issue":"6","key":"9133_CR185","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/ar2337","volume":"9","author":"U Muller-Ladner","year":"2007","unstructured":"Muller-Ladner U et al (2007) Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts. Arthritis Res Ther 9(6):223","journal-title":"Arthritis Res Ther"},{"key":"9133_CR186","doi-asserted-by":"crossref","unstructured":"Nemtsova MV et al (2019) Epigenetic changes in the pathogenesis of rheumatoid arthritis. Front Genet 10","DOI":"10.3389\/fgene.2019.00570"},{"key":"9133_CR187","doi-asserted-by":"crossref","unstructured":"Brandt B et al (2019) DNA methylation-governed gene expression in autoimmune arthritis.\u00a0Int J Mol Sci\u00a020(22)","DOI":"10.3390\/ijms20225646"},{"issue":"5","key":"9133_CR188","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/nrrheum.2009.55","volume":"5","author":"E Karouzakis","year":"2009","unstructured":"Karouzakis E et al (2009) Epigenetic control in rheumatoid arthritis synovial fibroblasts. Nat Rev Rheumatol 5(5):266\u2013272","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"9133_CR189","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1002\/art.25018","volume":"60","author":"E Karouzakis","year":"2009","unstructured":"Karouzakis E et al (2009) DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 60(12):3613\u20133622","journal-title":"Arthritis Rheum"},{"key":"9133_CR190","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.3389\/fimmu.2018.02118","volume":"9","author":"V Cecchinato","year":"2018","unstructured":"Cecchinato V et al (2018) Redox-Mediated mechanisms fuel monocyte responses to CXCL12\/HMGB1 in active rheumatoid arthritis. Front Immunol 9:2118","journal-title":"Front Immunol"},{"issue":"8","key":"9133_CR191","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/gene.2011.45","volume":"12","author":"E Karouzakis","year":"2011","unstructured":"Karouzakis E et al (2011) DNA methylation regulates the expression of CXCL12 in rheumatoid arthritis synovial fibroblasts. Genes Immun 12(8):643\u2013652","journal-title":"Genes Immun"},{"issue":"6","key":"9133_CR192","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/d41573-019-00077-w","volume":"18","author":"M Cully","year":"2019","unstructured":"Cully M (2019) CD40L-targeting protein cools rheumatoid arthritis. Nat Rev Drug Discov 18(6):417","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"9133_CR193","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clim.2012.07.006","volume":"145","author":"J Liao","year":"2012","unstructured":"Liao J et al (2012) CD40L demethylation in CD4(+) T cells from women with rheumatoid arthritis. Clin Immunol 145(1):13\u201318","journal-title":"Clin Immunol"},{"issue":"11","key":"9133_CR194","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1136\/annrheumdis-2019-215355","volume":"78","author":"J Rodriguez-Ubreva","year":"2019","unstructured":"Rodriguez-Ubreva J et al (2019) Inflammatory cytokines shape a changing DNA methylome in monocytes mirroring disease activity in rheumatoid arthritis. Ann Rheum Dis 78(11):1505\u20131516","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"9133_CR195","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1093\/rheumatology\/keaa649","volume":"60","author":"I Liebold","year":"2021","unstructured":"Liebold I et al (2021) Peripheral blood mononuclear cells are hypomethylated in active rheumatoid arthritis and methylation correlates with disease activity. Rheumatology (Oxford) 60(4):1984\u20131995","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"9133_CR196","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1002\/art.38715","volume":"66","author":"AP Cribbs","year":"2014","unstructured":"Cribbs AP et al (2014) Treg cell function in rheumatoid arthritis is compromised by CTLA-4 promoter methylation resulting in a failure to activate the indoleamine 2,3-dioxygenase pathway. Arthritis Rheumatol 66(9):2344\u201354","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"9133_CR197","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/imm.12754","volume":"152","author":"K Klocke","year":"2017","unstructured":"Klocke K et al (2017) CTLA-4 expressed by FOXP3(+) regulatory T cells prevents inflammatory tissue attack and not T-cell priming in arthritis. Immunology 152(1):125\u2013137","journal-title":"Immunology"},{"issue":"2","key":"9133_CR198","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.molimm.2012.01.006","volume":"51","author":"ZT Xue","year":"2012","unstructured":"Xue ZT et al (2012) An epigenetic mechanism for high, synergistic expression of indoleamine 2,3-dioxygenase 1 (IDO1) by combined treatment with zebularine and IFN-gamma: potential therapeutic use in autoimmune diseases. Mol Immunol 51(2):101\u2013111","journal-title":"Mol Immunol"},{"issue":"8","key":"9133_CR199","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/art.40877","volume":"71","author":"DM Toth","year":"2019","unstructured":"Toth DM et al (2019) Amelioration of autoimmune arthritis in mice treated with the DNA methyltransferase inhibitor 5\u2019-Azacytidine. Arthritis Rheumatol 71(8):1265\u20131275","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"9133_CR200","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/art.34340","volume":"64","author":"E Karouzakis","year":"2012","unstructured":"Karouzakis E et al (2012) Increased recycling of polyamines is associated with global DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 64(6):1809\u20131817","journal-title":"Arthritis Rheum"},{"issue":"7","key":"9133_CR201","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/art.38574","volume":"66","author":"M Neidhart","year":"2014","unstructured":"Neidhart M et al (2014) Inhibition of spermidine\/spermine N1-acetyltransferase activity: a new therapeutic concept in rheumatoid arthritis. Arthritis Rheumatol 66(7):1723\u20131733","journal-title":"Arthritis Rheumatol"},{"key":"9133_CR202","doi-asserted-by":"publisher","DOI":"10.3390\/cells8090953","author":"M Ciechomska","year":"2019","unstructured":"Ciechomska M et al (2019) DNA methylation as a future therapeutic and diagnostic target in rheumatoid arthritis. Cells. https:\/\/doi.org\/10.3390\/cells8090953","journal-title":"Cells"},{"issue":"4","key":"9133_CR203","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/carcin\/bgq285","volume":"32","author":"V Nandakumar","year":"2011","unstructured":"Nandakumar V et al (2011) (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1\/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. Carcinogenesis 32(4):537\u2013544","journal-title":"Carcinogenesis"},{"issue":"1","key":"9133_CR204","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13075-015-0748-5","volume":"17","author":"MC de Andres","year":"2015","unstructured":"de Andres MC et al (2015) Assessment of global DNA methylation in peripheral blood cell subpopulations of early rheumatoid arthritis before and after methotrexate. Arthritis Res Ther 17(1):233","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"9133_CR205","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1136\/ard.2011.154211","volume":"71","author":"AM Grabiec","year":"2012","unstructured":"Grabiec AM et al (2012) Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis 71(3):424\u2013431","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9133_CR206","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13075-018-1638-4","volume":"20","author":"C Angiolilli","year":"2018","unstructured":"Angiolilli C et al (2018) Control of cytokine mRNA degradation by the histone deacetylase inhibitor ITF2357 in rheumatoid arthritis fibroblast-like synoviocytes: beyond transcriptional regulation. Arthritis Res Ther 20(1):148","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"9133_CR207","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10753-015-0220-3","volume":"39","author":"H Chen","year":"2016","unstructured":"Chen H et al (2016) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, induces apoptosis in rheumatoid arthritis fibroblast-like synoviocytes. Inflammation 39(1):39\u201346","journal-title":"Inflammation"},{"issue":"10","key":"9133_CR208","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1002\/art.20709","volume":"50","author":"K Nishida","year":"2004","unstructured":"Nishida K et al (2004) Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1\/Cip1) expression. Arthritis Rheum 50(10):3365\u20133376","journal-title":"Arthritis Rheum"},{"issue":"1","key":"9133_CR209","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13075-020-02258-0","volume":"22","author":"JK Park","year":"2020","unstructured":"Park JK et al (2020) Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis. Arthritis Res Ther 22(1):176","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"9133_CR210","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrneurol.2012.43","volume":"8","author":"RR Voskuhl","year":"2012","unstructured":"Voskuhl RR, Gold SM (2012) Sex-related factors in multiple sclerosis susceptibility and progression. Nat Rev Neurol 8(5):255\u2013263","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"9133_CR211","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/joim.13045","volume":"288","author":"L Kular","year":"2020","unstructured":"Kular L, Jagodic M (2020) Epigenetic insights into multiple sclerosis disease progression. J Intern Med 288(1):82\u2013102","journal-title":"J Intern Med"},{"issue":"1","key":"9133_CR212","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrneurol.2012.226","volume":"9","author":"MW Koch","year":"2013","unstructured":"Koch MW et al (2013) Epigenetic changes in patients with multiple sclerosis. Nat Rev Neurol 9(1):35\u201343","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"9133_CR213","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12974-019-1667-1","volume":"17","author":"N Celarain","year":"2020","unstructured":"Celarain N, Tomas-Roig J (2020) Aberrant DNA methylation profile exacerbates inflammation and neurodegeneration in multiple sclerosis patients. J Neuroinflammation 17(1):21","journal-title":"J Neuroinflammation"},{"issue":"3","key":"9133_CR214","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1159\/000331474","volume":"19","author":"C Borner","year":"2012","unstructured":"Borner C et al (2012) Regulation of opioid and cannabinoid receptor genes in human neuroblastoma and T cells by the epigenetic modifiers trichostatin A and 5-aza-2\u2019-deoxycytidine. Neuroimmunomodulation 19(3):180\u2013186","journal-title":"Neuroimmunomodulation"},{"issue":"12","key":"9133_CR215","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/jcp.24641","volume":"229","author":"K Mangano","year":"2014","unstructured":"Mangano K et al (2014) Hypomethylating agent 5-aza-2\u2019-deoxycytidine (DAC) ameliorates multiple sclerosis in mouse models. J Cell Physiol 229(12):1918\u20131925","journal-title":"J Cell Physiol"},{"issue":"1","key":"9133_CR216","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/s41467-019-09984-3","volume":"10","author":"NY Souren","year":"2019","unstructured":"Souren NY et al (2019) DNA methylation signatures of monozygotic twins clinically discordant for multiple sclerosis. Nat Commun 10(1):2094","journal-title":"Nat Commun"},{"issue":"1\u20132","key":"9133_CR217","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jneuroim.2005.02.022","volume":"164","author":"S Camelo","year":"2005","unstructured":"Camelo S et al (2005) Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol 164(1\u20132):10\u201321","journal-title":"J Neuroimmunol"},{"key":"9133_CR218","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jaut.2016.07.011","volume":"75","author":"C Donas","year":"2016","unstructured":"Donas C et al (2016) The histone demethylase inhibitor GSK-J4 limits inflammation through the induction of a tolerogenic phenotype on DCs. J Autoimmun 75:105\u2013117","journal-title":"J Autoimmun"},{"key":"9133_CR219","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1038\/ncomms6797","volume":"5","author":"S Noda","year":"2014","unstructured":"Noda S et al (2014) Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. Nat Commun 5:5797","journal-title":"Nat Commun"},{"issue":"6","key":"9133_CR220","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/annrheumdis-2012-203194","volume":"73","author":"C Dees","year":"2014","unstructured":"Dees C et al (2014) The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann Rheum Dis 73(6):1232\u20131239","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"9133_CR221","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1136\/annrheumdis-2017-212265","volume":"77","author":"Y Zhang","year":"2018","unstructured":"Zhang Y et al (2018) Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis. Ann Rheum Dis 77(5):744\u2013751","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9133_CR222","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/bjd.12913","volume":"171","author":"YY Wang","year":"2014","unstructured":"Wang YY et al (2014) DNA hypermethylation of the forkhead box protein 3 (FOXP3) promoter in CD4\u2009+\u2009T cells of patients with systemic sclerosis. Br J Dermatol 171(1):39\u201347","journal-title":"Br J Dermatol"},{"issue":"1","key":"9133_CR223","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-016-0281-2","volume":"9","author":"G Fransolet","year":"2016","unstructured":"Fransolet G et al (2016) Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. J Hematol Oncol 9(1):53","journal-title":"J Hematol Oncol"},{"issue":"4","key":"9133_CR224","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1136\/annrheumdis-2012-201615","volume":"72","author":"M Kramer","year":"2013","unstructured":"Kramer M et al (2013) Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Ann Rheum Dis 72(4):614\u2013620","journal-title":"Ann Rheum Dis"},{"issue":"341","key":"9133_CR225","doi-asserted-by":"publisher","first-page":"ra84","DOI":"10.1126\/scisignal.2004592","volume":"7","author":"S Svegliati","year":"2014","unstructured":"Svegliati S et al (2014) Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis. Sci Signal 7(341):ra84","journal-title":"Sci Signal"},{"issue":"43","key":"9133_CR226","doi-asserted-by":"publisher","first-page":"69321","DOI":"10.18632\/oncotarget.12504","volume":"7","author":"K Akamata","year":"2016","unstructured":"Akamata K et al (2016) SIRT3 is attenuated in systemic sclerosis skin and lungs, and its Pharmacologic activation mitigates organ fibrosis. Oncotarget 7(43):69321\u201369336","journal-title":"Oncotarget"},{"issue":"6","key":"9133_CR227","doi-asserted-by":"publisher","first-page":"L945","DOI":"10.1152\/ajplung.00473.2016","volume":"312","author":"AE Wyman","year":"2017","unstructured":"Wyman AE et al (2017) Sirtuin 7 is decreased in pulmonary fibrosis and regulates the fibrotic phenotype of lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 312(6):L945\u2013L958","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"9133_CR228","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1172\/jci.insight.150871","volume":"7","author":"S Vichaikul","year":"2022","unstructured":"Vichaikul S et al (2022) Inhibition of bromodomain extraterminal histone readers alleviates skin fibrosis in experimental models of scleroderma. JCI Insight 7:9","journal-title":"JCI Insight"},{"issue":"5","key":"9133_CR229","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/jid.2012.479","volume":"133","author":"AK Ghosh","year":"2013","unstructured":"Ghosh AK et al (2013) p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-beta: epigenetic feed-forward amplification of fibrosis. J Invest Dermatol 133(5):1302\u20131310","journal-title":"J Invest Dermatol"},{"issue":"5","key":"9133_CR230","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","volume":"11","author":"J Welti","year":"2021","unstructured":"Welti J et al (2021) Targeting the p300\/CBP axis in lethal prostate cancer. Cancer Discov 11(5):1118\u20131137","journal-title":"Cancer Discov"},{"issue":"1","key":"9133_CR231","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1136\/annrheumdis-2017-211501","volume":"77","author":"C Bergmann","year":"2018","unstructured":"Bergmann C et al (2018) The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis. Ann Rheum Dis 77(1):150\u2013158","journal-title":"Ann Rheum Dis"},{"key":"9133_CR232","doi-asserted-by":"publisher","first-page":"20314","DOI":"10.1038\/srep20314","volume":"6","author":"Q Yan","year":"2016","unstructured":"Yan Q et al (2016) Targeting miR-155 to treat experimental scleroderma. Sci Rep 6:20314","journal-title":"Sci Rep"},{"issue":"9","key":"9133_CR233","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1517\/14728222.2012.708339","volume":"16","author":"WJ Peng","year":"2012","unstructured":"Peng WJ et al (2012) MicroRNA-29: a potential therapeutic target for systemic sclerosis. Expert Opin Ther Targets 16(9):875\u2013879","journal-title":"Expert Opin Ther Targets"},{"issue":"7863","key":"9133_CR234","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41586-021-03552-w","volume":"594","author":"J Chiou","year":"2021","unstructured":"Chiou J et al (2021) Interpreting type 1 diabetes risk with genetics and single-cell epigenomics. Nature 594(7863):398\u2013402","journal-title":"Nature"},{"issue":"6","key":"9133_CR235","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1542\/peds.2013-1652","volume":"132","author":"K Stankov","year":"2013","unstructured":"Stankov K et al (2013) Genetic and epigenetic factors in etiology of diabetes mellitus type 1. Pediatrics 132(6):1112\u20131122","journal-title":"Pediatrics"},{"issue":"4","key":"9133_CR236","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.immuni.2010.04.001","volume":"32","author":"JA Todd","year":"2010","unstructured":"Todd JA (2010) Etiology of type 1 diabetes. Immunity 32(4):457\u2013467","journal-title":"Immunity"},{"issue":"12","key":"9133_CR237","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00109-009-0530-8","volume":"87","author":"Q Zheng","year":"2009","unstructured":"Zheng Q et al (2009) Induction of Foxp3 demethylation increases regulatory CD4\u2009+\u2009CD25\u2009+\u2009T cells and prevents the occurrence of diabetes in mice. J Mol Med (Berl) 87(12):1191\u20131205","journal-title":"J Mol Med (Berl)"},{"issue":"34","key":"9133_CR238","doi-asserted-by":"publisher","first-page":"14066","DOI":"10.1074\/jbc.M117.784280","volume":"292","author":"GS Manzar","year":"2017","unstructured":"Manzar GS et al (2017) Demethylation of induced pluripotent stem cells from type 1 diabetic patients enhances differentiation into functional pancreatic beta cells. J Biol Chem 292(34):14066\u201314079","journal-title":"J Biol Chem"},{"key":"9133_CR239","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.trsl.2017.05.002","volume":"185","author":"A Zullo","year":"2017","unstructured":"Zullo A et al (2017) Epigenetics and type 1 diabetes: mechanisms and translational applications. Transl Res 185:85\u201393","journal-title":"Transl Res"},{"key":"9133_CR240","doi-asserted-by":"publisher","first-page":"108490","DOI":"10.1016\/j.intimp.2021.108490","volume":"103","author":"V Patel","year":"2022","unstructured":"Patel V et al (2022) Epigenetic drug ameliorated type 1 diabetes via decreased generation of Th1 and Th17 subsets and restoration of self-tolerance in CD4(+) T cells. Int Immunopharmacol 103:108490","journal-title":"Int Immunopharmacol"},{"issue":"5\u20136","key":"9133_CR241","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2119\/molmed.2010.00152","volume":"17","author":"EC Lewis","year":"2011","unstructured":"Lewis EC et al (2011) The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet beta cells in vivo and in vitro. Mol Med 17(5\u20136):369\u201377","journal-title":"Mol Med"},{"issue":"2","key":"9133_CR242","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/intimm\/dxh030","volume":"16","author":"M Fujimoto","year":"2004","unstructured":"Fujimoto M et al (2004) Inadequate induction of suppressor of cytokine signaling-1 causes systemic autoimmune diseases. Int Immunol 16(2):303\u2013314","journal-title":"Int Immunol"},{"issue":"2","key":"9133_CR243","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1084\/jem.194.2.189","volume":"194","author":"M Ernst","year":"2001","unstructured":"Ernst M et al (2001) Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, Gastrointestinal ulceration, and failure of uterine implantation. J Exp Med 194(2):189\u2013203","journal-title":"J Exp Med"},{"issue":"6","key":"9133_CR244","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1172\/JCI25660","volume":"116","author":"PK Wong","year":"2006","unstructured":"Wong PK et al (2006) SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J Clin Invest 116(6):1571\u20131581","journal-title":"J Clin Invest"},{"issue":"7","key":"9133_CR245","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1084\/jem.20020619","volume":"196","author":"T Atsumi","year":"2002","unstructured":"Atsumi T et al (2002) A point mutation of Tyr-759 in Interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med 196(7):979\u2013990","journal-title":"J Exp Med"},{"issue":"2","key":"9133_CR246","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ajhg.2010.01.017","volume":"86","author":"E Jakkula","year":"2010","unstructured":"Jakkula E et al (2010) Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am J Hum Genet 86(2):285\u2013291","journal-title":"Am J Hum Genet"},{"key":"9133_CR247","doi-asserted-by":"publisher","first-page":"1872593","DOI":"10.1155\/2019\/1872593","volume":"2019","author":"A Cramer","year":"2019","unstructured":"Cramer A et al (2019) Role of SOCS2 in the regulation of immune response and development of the experimental autoimmune encephalomyelitis. Mediators Inflamm 2019:1872593","journal-title":"Mediators Inflamm"},{"issue":"5","key":"9133_CR248","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.4049\/jimmunol.181.5.3167","volume":"181","author":"H Qin","year":"2008","unstructured":"Qin H et al (2008) Expression and functional significance of SOCS-1 and SOCS-3 in astrocytes. J Immunol 181(5):3167\u20133176","journal-title":"J Immunol"},{"issue":"9","key":"9133_CR249","doi-asserted-by":"publisher","first-page":"5714","DOI":"10.4049\/jimmunol.172.9.5714","volume":"172","author":"MM Chong","year":"2004","unstructured":"Chong MM et al (2004) Suppressor of cytokine signaling-1 overexpression protects pancreatic beta cells from CD8\u2009+\u2009T cell-mediated autoimmune destruction. J Immunol 172(9):5714\u20135721","journal-title":"J Immunol"},{"issue":"21","key":"9133_CR250","doi-asserted-by":"publisher","first-page":"12191","DOI":"10.1073\/pnas.211445998","volume":"98","author":"AE Karlsen","year":"2001","unstructured":"Karlsen AE et al (2001) Suppressor of cytokine signaling 3 (SOCS-3) protects beta -cells against interleukin-1beta - and interferon-gamma -mediated toxicity. Proc Natl Acad Sci U S A 98(21):12191\u201312196","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"9133_CR251","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1038\/s41401-024-01242-7","volume":"45","author":"JH Li","year":"2024","unstructured":"Li JH et al (2024) GPR41 deficiency aggravates type 1 diabetes in streptozotocin-treated mice by promoting dendritic cell maturation. Acta Pharmacol Sin 45(7):1466\u20131476","journal-title":"Acta Pharmacol Sin"},{"issue":"7","key":"9133_CR252","doi-asserted-by":"publisher","first-page":"e40343","DOI":"10.1371\/journal.pone.0040343","volume":"7","author":"A Uto-Konomi","year":"2012","unstructured":"Uto-Konomi A et al (2012) Dysregulation of suppressor of cytokine signaling 3 in keratinocytes causes skin inflammation mediated by interleukin-20 receptor-related cytokines. PLoS One 7(7):e40343","journal-title":"PLoS One"},{"key":"9133_CR253","doi-asserted-by":"publisher","first-page":"107327482514066","DOI":"10.1177\/10732748251406677","volume":"32","author":"S Mukherjee","year":"2025","unstructured":"Mukherjee S et al (2025) The role of nuclear Factor-\u03baB in cancer immunity and immunoediting. Cancer Control 32:10732748251406677","journal-title":"Cancer Control"},{"key":"9133_CR254","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2024-001445","author":"Y Setyawan","year":"2025","unstructured":"Setyawan Y et al (2025) Comparison of TLR4, NF-\u03baB and IRF3 expression in kidney tissue between lupus nephritis (LN) and systemic lupus erythematosus (SLE): a pristane-induced lupus mice model study. Lupus Sci Med. https:\/\/doi.org\/10.1136\/lupus-2024-001445","journal-title":"Lupus Sci Med"},{"key":"9133_CR255","doi-asserted-by":"crossref","unstructured":"Deng J et al (2025) The IL-23\/IL-17\/NF-\u03baB signaling pathway in rheumatoid arthritis: molecular mechanisms and therapeutic agents. Med Res Rev","DOI":"10.1002\/med.70024"},{"key":"9133_CR256","doi-asserted-by":"publisher","first-page":"1549102","DOI":"10.3389\/fimmu.2025.1549102","volume":"16","author":"D Dai","year":"2025","unstructured":"Dai D et al (2025) Porphyromonas gingivalis exacerbates experimental autoimmune encephalomyelitis by driving Th1 differentiation via ZAP70\/NF-\u03baB signaling. Front Immunol 16:1549102","journal-title":"Front Immunol"},{"key":"9133_CR257","doi-asserted-by":"crossref","unstructured":"Li Z et al (2025) Innate immune-cell-derived BAFF promotes inflammatory response of ICOSL\u207a B cells via non-canonical NF-\u03baB in diabetic autoimmunity. Mol Ther","DOI":"10.1016\/j.ymthe.2025.12.003"},{"issue":"4","key":"9133_CR258","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1158\/1541-7786.MCR-10-0511","volume":"9","author":"T Fan","year":"2011","unstructured":"Fan T et al (2011) EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by Inhibition of p21\/CDKN1A expression. Mol Cancer Res 9(4):418\u2013429","journal-title":"Mol Cancer Res"},{"issue":"6","key":"9133_CR259","doi-asserted-by":"publisher","first-page":"152374","DOI":"10.1016\/j.prp.2019.03.003","volume":"215","author":"J Xu","year":"2019","unstructured":"Xu J et al (2019) EZH2 promotes gastric cancer cells proliferation by repressing p21 expression. Pathol Res Pract 215(6):152374","journal-title":"Pathol Res Pract"},{"key":"9133_CR260","doi-asserted-by":"publisher","first-page":"1002741","DOI":"10.3389\/fphar.2022.1002741","volume":"13","author":"Y Yang","year":"2022","unstructured":"Yang Y et al (2022) EZH2: its regulation and roles in immune disturbance of SLE. Front Pharmacol 13:1002741","journal-title":"Front Pharmacol"},{"issue":"3","key":"9133_CR261","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3892\/mmr.2017.6150","volume":"15","author":"Z Ye","year":"2017","unstructured":"Ye Z et al (2017) Lnc\u2013IL7R promotes the growth of fibroblast\u2013like synoviocytes through interaction with enhancer of Zeste homolog 2 in rheumatoid arthritis. Mol Med Rep 15(3):1412\u20131418","journal-title":"Mol Med Rep"},{"key":"9133_CR262","doi-asserted-by":"publisher","first-page":"109052","DOI":"10.1016\/j.bioorg.2025.109052","volume":"165","author":"B Han","year":"2025","unstructured":"Han B et al (2025) The role and potential therapeutic application of HDAC6 inhibitors in inflammation-related diseases: a medicinal chemistry perspective. Bioorg Chem 165:109052","journal-title":"Bioorg Chem"},{"key":"9133_CR263","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/ijms21186873","volume":"21","author":"HY Cho","year":"2020","unstructured":"Cho HY et al (2020) Combination of ACY-241 and JQ1 synergistically suppresses metastasis of HNSCC via regulation of MMP-2 and MMP-9. Int J Mol Sci 21:18","journal-title":"Int J Mol Sci"},{"issue":"9","key":"9133_CR264","doi-asserted-by":"publisher","first-page":"11519","DOI":"10.1007\/s00210-025-04127-6","volume":"398","author":"HAA Harirah","year":"2025","unstructured":"Harirah HAA et al (2025) Targeting EZH2 in autoimmune diseases: unraveling epigenetic regulation and therapeutic potential. Naunyn Schmiedebergs Arch Pharmacol 398(9):11519\u201311539","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"11","key":"9133_CR265","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1136\/annrheumdis-2015-208410","volume":"75","author":"M Zhao","year":"2016","unstructured":"Zhao M et al (2016) IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus. Ann Rheum Dis 75(11):1998\u20132006","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"9133_CR266","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41587-020-0621-1","volume":"38","author":"K Garber","year":"2020","unstructured":"Garber K (2020) Histone-writer cancer drugs enter center stage. Nat Biotechnol 38(8):909\u2013912","journal-title":"Nat Biotechnol"},{"issue":"7068","key":"9133_CR267","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nature04303","volume":"438","author":"J Krutzfeldt","year":"2005","unstructured":"Krutzfeldt J et al (2005) Silencing of MicroRNAs in vivo with \u2018antagomirs\u2019. Nature 438(7068):685\u2013689","journal-title":"Nature"},{"key":"9133_CR268","doi-asserted-by":"publisher","first-page":"1688995","DOI":"10.3389\/fimmu.2025.1688995","volume":"16","author":"T Frlic","year":"2025","unstructured":"Frlic T, Pavlin M (2025) Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy. Front Immunol 16:1688995","journal-title":"Front Immunol"},{"key":"9133_CR269","doi-asserted-by":"publisher","first-page":"1623117","DOI":"10.3389\/fimmu.2025.1623117","volume":"16","author":"Y Cao","year":"2025","unstructured":"Cao Y et al (2025) Targeting the epigenome and tumor heterogeneity: advances in immunotherapy for chemoresistant metastatic colorectal cancer. Front Immunol 16:1623117","journal-title":"Front Immunol"},{"issue":"1","key":"9133_CR270","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s43556-025-00373-5","volume":"6","author":"C Ma","year":"2025","unstructured":"Ma C et al (2025) Epigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications. Mol Biomed 6(1):132","journal-title":"Mol Biomed"},{"key":"9133_CR271","doi-asserted-by":"crossref","unstructured":"Roussel-Simonin C et al (2025) Exploring KAT6 as a therapeutic target in breast cancer: epigenetic approaches for precision medicine. NPJ Breast Cancer","DOI":"10.1038\/s41523-025-00858-0"},{"key":"9133_CR272","doi-asserted-by":"publisher","first-page":"14853","DOI":"10.2147\/IJN.S566173","volume":"20","author":"T Gao","year":"2025","unstructured":"Gao T et al (2025) Advancing epigenetic combination therapy in oncology: multifunctional Nano-Drug delivery systems for synergistic efficacy and precision modulation. Int J Nanomed 20:14853\u201314883","journal-title":"Int J Nanomed"},{"issue":"1","key":"9133_CR273","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13148-023-01605-7","volume":"15","author":"I Fernandez-De-Los-Reyes","year":"2023","unstructured":"Fernandez-De-Los-Reyes I et al (2023) ZEB1 hypermethylation is associated with better prognosis in patients with colon cancer. Clin Epigenetics 15(1):193","journal-title":"Clin Epigenetics"},{"issue":"12","key":"9133_CR274","first-page":"e70389","volume":"8","author":"B Faryal","year":"2025","unstructured":"Faryal B (2025) Epigenetic regulation of autophagy in breast cancer: implications for biomarker discovery and personalized therapy. Cancer Rep Hoboken 8(12):e70389","journal-title":"Cancer Rep Hoboken"},{"key":"9133_CR275","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2025.5824","author":"L Liu","year":"2026","unstructured":"Liu L et al (2026) The tumor microenvironment in lung cancer: heterogeneity, therapeutic resistance and emerging treatment strategies (Review). Int J Oncol. https:\/\/doi.org\/10.3892\/ijo.2025.5824","journal-title":"Int J Oncol"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09133-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-026-09133-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09133-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:02:37Z","timestamp":1777287757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-026-09133-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":275,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9133"],"URL":"https:\/\/doi.org\/10.1007\/s12016-026-09133-x","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"22 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. All cited materials have been published in public.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}